<?xml version='1.0' encoding='utf-8'?>
<document id="25975718"><sentence text="Quantification of the impact of enzyme-inducing antiepileptic drugs on irinotecan pharmacokinetics and SN-38 exposure."><entity charOffset="71-81" id="DDI-PubMed.25975718.s1.e0" text="irinotecan" /></sentence><sentence text="The population pharmacokinetic model reported here was developed using data from 2 phase 2 trials of irinotecan for treatment of malignant glioma to quantify the impact of concomitant therapy with enzyme-inducing antiepileptic drugs (EIAEDs) on irinotecan pharmacokinetics"><entity charOffset="101-111" id="DDI-PubMed.25975718.s2.e0" text="irinotecan" /><entity charOffset="245-255" id="DDI-PubMed.25975718.s2.e1" text="irinotecan" /><pair ddi="false" e1="DDI-PubMed.25975718.s2.e0" e2="DDI-PubMed.25975718.s2.e0" /><pair ddi="false" e1="DDI-PubMed.25975718.s2.e0" e2="DDI-PubMed.25975718.s2.e1" /></sentence><sentence text=" Patients received weekly irinotecan doses of 100 to 400â€‰mg/m(2) , and plasma samples were collected and analyzed for irinotecan and its APC, SN-38, and SN-38G metabolites"><entity charOffset="26-36" id="DDI-PubMed.25975718.s3.e0" text="irinotecan" /><entity charOffset="118-128" id="DDI-PubMed.25975718.s3.e1" text="irinotecan" /><pair ddi="false" e1="DDI-PubMed.25975718.s3.e0" e2="DDI-PubMed.25975718.s3.e0" /><pair ddi="false" e1="DDI-PubMed.25975718.s3.e0" e2="DDI-PubMed.25975718.s3.e1" /></sentence><sentence text=" Nonlinear mixed-effects modeling was employed for population pharmacokinetic analysis" /><sentence text=" Concomitant therapy with phenytoin, phenobarbital, or carbamazepine increased the clearances of irinotecan, SN-38, and SN-38G but not APC"><entity charOffset="26-35" id="DDI-PubMed.25975718.s5.e0" text="phenytoin" /><entity charOffset="37-50" id="DDI-PubMed.25975718.s5.e1" text="phenobarbital" /><entity charOffset="55-68" id="DDI-PubMed.25975718.s5.e2" text="carbamazepine" /><entity charOffset="97-107" id="DDI-PubMed.25975718.s5.e3" text="irinotecan" /><entity charOffset="109-114" id="DDI-PubMed.25975718.s5.e4" text="SN-38" /><entity charOffset="120-126" id="DDI-PubMed.25975718.s5.e5" text="SN-38G" /><pair ddi="false" e1="DDI-PubMed.25975718.s5.e0" e2="DDI-PubMed.25975718.s5.e0" /><pair ddi="false" e1="DDI-PubMed.25975718.s5.e0" e2="DDI-PubMed.25975718.s5.e1" /><pair ddi="false" e1="DDI-PubMed.25975718.s5.e0" e2="DDI-PubMed.25975718.s5.e2" /><pair ddi="false" e1="DDI-PubMed.25975718.s5.e0" e2="DDI-PubMed.25975718.s5.e3" /><pair ddi="false" e1="DDI-PubMed.25975718.s5.e0" e2="DDI-PubMed.25975718.s5.e4" /><pair ddi="false" e1="DDI-PubMed.25975718.s5.e0" e2="DDI-PubMed.25975718.s5.e5" /><pair ddi="false" e1="DDI-PubMed.25975718.s5.e1" e2="DDI-PubMed.25975718.s5.e1" /><pair ddi="false" e1="DDI-PubMed.25975718.s5.e1" e2="DDI-PubMed.25975718.s5.e2" /><pair ddi="false" e1="DDI-PubMed.25975718.s5.e1" e2="DDI-PubMed.25975718.s5.e3" /><pair ddi="false" e1="DDI-PubMed.25975718.s5.e1" e2="DDI-PubMed.25975718.s5.e4" /><pair ddi="false" e1="DDI-PubMed.25975718.s5.e1" e2="DDI-PubMed.25975718.s5.e5" /><pair ddi="false" e1="DDI-PubMed.25975718.s5.e2" e2="DDI-PubMed.25975718.s5.e2" /><pair ddi="false" e1="DDI-PubMed.25975718.s5.e2" e2="DDI-PubMed.25975718.s5.e3" /><pair ddi="false" e1="DDI-PubMed.25975718.s5.e2" e2="DDI-PubMed.25975718.s5.e4" /><pair ddi="false" e1="DDI-PubMed.25975718.s5.e2" e2="DDI-PubMed.25975718.s5.e5" /><pair ddi="false" e1="DDI-PubMed.25975718.s5.e3" e2="DDI-PubMed.25975718.s5.e3" /><pair ddi="false" e1="DDI-PubMed.25975718.s5.e3" e2="DDI-PubMed.25975718.s5.e4" /><pair ddi="false" e1="DDI-PubMed.25975718.s5.e3" e2="DDI-PubMed.25975718.s5.e5" /><pair ddi="false" e1="DDI-PubMed.25975718.s5.e4" e2="DDI-PubMed.25975718.s5.e4" /><pair ddi="false" e1="DDI-PubMed.25975718.s5.e4" e2="DDI-PubMed.25975718.s5.e5" /></sentence><sentence text=" SN-38 clearance was 2-fold higher with concomitant EIAED use, resulting in 40% lower SN-38 exposure"><entity charOffset="1-6" id="DDI-PubMed.25975718.s6.e0" text="SN-38" /><entity charOffset="86-91" id="DDI-PubMed.25975718.s6.e1" text="SN-38" /><pair ddi="false" e1="DDI-PubMed.25975718.s6.e0" e2="DDI-PubMed.25975718.s6.e0" /><pair ddi="false" e1="DDI-PubMed.25975718.s6.e0" e2="DDI-PubMed.25975718.s6.e1" /></sentence><sentence text=" Evaluation of additional covariates revealed no clinically relevant effects of sex or concomitant corticosteroid use"><entity charOffset="99-113" id="DDI-PubMed.25975718.s7.e0" text="corticosteroid" /></sentence><sentence text=" The population pharmacokinetic model suggests that a 1" /><sentence text="7-fold increase in irinotecan dose may compensate for decreases in SN-38 exposure in the presence of concomitant EIAEDs"><entity charOffset="19-29" id="DDI-PubMed.25975718.s9.e0" text="irinotecan" /><entity charOffset="67-76" id="DDI-PubMed.25975718.s9.e1" text="SN-38" /><pair ddi="false" e1="DDI-PubMed.25975718.s9.e0" e2="DDI-PubMed.25975718.s9.e0" /><pair ddi="false" e1="DDI-PubMed.25975718.s9.e0" e2="DDI-PubMed.25975718.s9.e1" /></sentence><sentence text=" Although slightly more conservative, this dose adjustment is consistent with those recommended based on increases in the maximally tolerated dose for malignant glioma patients receiving EIAEDs and may be an appropriate starting point for further investigation when extrapolating to other cancer types or alternative regimens" /><sentence text=" " /></document>